Skip to content

Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) | Lower Urinary Track Symptoms

Lower urinary symptoms (LUTS) affect older men and their frequency and severity increase with age. According to Berry et al., the histological diagnosis of benign prostatic hyperplasia (BPH) increases from 25% in the group age between 40 to 49 years to 80% in the group age between 70 to 79 years (1). However, this hyperplasia can lead to a bladder outlet obstruction (BOO) secondary to benign prostatic enlargement (BPE), causing storage and voiding symptoms, associated with a considerable impairment of the quality of life (2).

Surgical therapy of BPH has continuously evolved in recent years. The current gold standard for the endoscopic treatment of BPH is the transurethral resection of the prostate (TURP). Other innovative techniques were developed including Urolift, transurethral laser enucleation (holmium, thulium) and Aquablation therapy. One of the latest technologies for the management of BPH are Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Bostocn Scientific, Marlborough, MA).

The purpose of the present study is to compare between patient experience, symptom relief and functional improvement when using the Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Boston Scientific, Marlborough, MA).

null

Participation Requirements

  • Sex:

    MALE

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Male subject with symptomatic BPH.
* Prostate size 30-100g.
* Able to complete the study protocol.

Exclusion Criteria:

* Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with follow-up requirements
* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
* Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
* Confirmed or suspected malignancy of prostate or bladder
* Active urinary tract infection (UTI) confirmed by culture
* History of overt urinary incontinence requiring use of pads NOTE: Pad usage for post-micturition dribble is acceptable
* Presence of confounding diagnoses impacting lower urinary tract symptoms or bladder function (e.g., urethral strictures, bladder neck contracture, neurogenic bladder, detrusor instability, bladder stones, etc.)
* History of chronic urinary retention (e.g., PVR ≥300mL on two separate occasions, or catheter dependent drainage)
* Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System
* Significant obstruction from median lobe (investigator opinion)
* Disease or other health condition that is not suitable for this study

Study Location

Centre Hospitalier de l'université de Montréal (CHUM)
Centre Hospitalier de l'université de Montréal (CHUM)
Montréal, Quebec
Canada

Contact Study Team

Backup Contact

Abbas Guennoun, MSc candidate

[email protected]
Primary Contact

Naeem Bhojani, MD

[email protected]
514-890-8000
Centre Hospitalier de l'université de Montréal (CHUM)
Centre Hospitalier de l'université de Montréal (CHUM)
Montreal, Quebec
Canada

Contact Study Team

Backup Contact

Abbas Guennoun, MSc candidate

[email protected]
Primary Contact

Naeem Bhojani, MD

[email protected]
514-890-8000
Study Sponsored By
Centre hospitalier de l'Université de Montréal (CHUM)
Participants Required
More Information
Study ID: NCT06769997